Use of Topical Timolol Maleate as Re-Epithelialization Agent for Treatment of Recalcitrant Wounds of Varying Etiologies

Brian A. Cahn; Ramanjot Kaur; Penelope A. Hirt; Catherine Tchanque-Fossuo; Sara E. Dahle; Robert S. Kirsner; Roslyn Rivkah Isseroff; Hadar Lev-Tov

doi:10.36849/JDD.2020.5306

Use of Topical Timolol Maleate as Re-Epithelialization Agent for Treatment of Recalcitrant Wounds of Varying Etiologies

Brian A. Cahn, Ramanjot Kaur, Penelope A. Hirt, Catherine Tchanque-Fossuo, Sara E. Dahle, Robert S. Kirsner, Roslyn Rivkah Isseroff, Hadar Lev-Tov

Dermatology & Cutaneous Surgery

Research output: Contribution to journal › Article › peer-review

Abstract

Chronic wounds are a source of severe morbidity to patients.1 Wounds are also a notable burden on the healthcare system, with reported prevalence of 4.64% in the U.S. and an annual cost of over 25 billion dollars.2,3 Moreover, wounds are associated with >15% of all skin disease-related deaths4 and the 5 year mortality of some chronic wounds is greater than that of many cancers.5.

Original language	English (US)
Pages (from-to)	1252-1256
Number of pages	5
Journal	Journal of drugs in dermatology : JDD
Volume	19
Issue number	12
DOIs	https://doi.org/10.36849/JDD.2020.5306
State	Published - Dec 1 2020

ASJC Scopus subject areas

Dermatology

Access to Document

10.36849/JDD.2020.5306

Fingerprint Dive into the research topics of 'Use of Topical Timolol Maleate as Re-Epithelialization Agent for Treatment of Recalcitrant Wounds of Varying Etiologies'. Together they form a unique fingerprint.

Cite this

Use of Topical Timolol Maleate as Re-Epithelialization Agent for Treatment of Recalcitrant Wounds of Varying Etiologies. / Cahn, Brian A.; Kaur, Ramanjot; Hirt, Penelope A.; Tchanque-Fossuo, Catherine; Dahle, Sara E.; Kirsner, Robert S.; Isseroff, Roslyn Rivkah; Lev-Tov, Hadar.

In: Journal of drugs in dermatology : JDD, Vol. 19, No. 12, 01.12.2020, p. 1252-1256.

Research output: Contribution to journal › Article › peer-review

@article{6745a194462144b1be4099958d8ba3f7,

title = "Use of Topical Timolol Maleate as Re-Epithelialization Agent for Treatment of Recalcitrant Wounds of Varying Etiologies",

abstract = "Chronic wounds are a source of severe morbidity to patients.1 Wounds are also a notable burden on the healthcare system, with reported prevalence of 4.64% in the U.S. and an annual cost of over 25 billion dollars.2,3 Moreover, wounds are associated with >15% of all skin disease-related deaths4 and the 5 year mortality of some chronic wounds is greater than that of many cancers.5.",

author = "Cahn, {Brian A.} and Ramanjot Kaur and Hirt, {Penelope A.} and Catherine Tchanque-Fossuo and Dahle, {Sara E.} and Kirsner, {Robert S.} and Isseroff, {Roslyn Rivkah} and Hadar Lev-Tov",

note = "Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine",

year = "2020",

month = dec,

day = "1",

doi = "10.36849/JDD.2020.5306",

language = "English (US)",

volume = "19",

pages = "1252--1256",

journal = "Journal of Drugs in Dermatology",

issn = "1545-9616",

publisher = "Journal of Drugs in Dermatology",

number = "12",

}

TY - JOUR

T1 - Use of Topical Timolol Maleate as Re-Epithelialization Agent for Treatment of Recalcitrant Wounds of Varying Etiologies

AU - Cahn, Brian A.

AU - Kaur, Ramanjot

AU - Hirt, Penelope A.

AU - Tchanque-Fossuo, Catherine

AU - Dahle, Sara E.

AU - Kirsner, Robert S.

AU - Isseroff, Roslyn Rivkah

AU - Lev-Tov, Hadar

N1 - Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Chronic wounds are a source of severe morbidity to patients.1 Wounds are also a notable burden on the healthcare system, with reported prevalence of 4.64% in the U.S. and an annual cost of over 25 billion dollars.2,3 Moreover, wounds are associated with >15% of all skin disease-related deaths4 and the 5 year mortality of some chronic wounds is greater than that of many cancers.5.

AB - Chronic wounds are a source of severe morbidity to patients.1 Wounds are also a notable burden on the healthcare system, with reported prevalence of 4.64% in the U.S. and an annual cost of over 25 billion dollars.2,3 Moreover, wounds are associated with >15% of all skin disease-related deaths4 and the 5 year mortality of some chronic wounds is greater than that of many cancers.5.

UR - http://www.scopus.com/inward/record.url?scp=85099008024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099008024&partnerID=8YFLogxK

U2 - 10.36849/JDD.2020.5306

DO - 10.36849/JDD.2020.5306

M3 - Article

C2 - 33346529

AN - SCOPUS:85099008024

VL - 19

SP - 1252

EP - 1256

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 12

ER -